Global KRAS Inhibitors Market Report to 2029: Featuring Ascentage Pharma, AstraZeneca, Boehringer Ingelheim and BridgeBio Pharma Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.
- Global KRAS Inhibitors Market Opportunity > USD 4 Billion By 2029
- Global KRAS Drug Market Growth In 2022 > 200%
- Number Of Approved Drugs: 2 Drugs
- Approved Drug Global & Regional Sales Insight
- Approved Drugs Patent, Price & Dosage Analysis
- Regional Analysis: USA, UK, China Europe, Japan, South Korea
- Number Of Drugs In Clinical Trials: > 60 Drugs
- Insight On All Drugs In Clinical Trials By Phase, Company, Country, Indication & Patient Segment
- AnBogen Therapeutics
- Applied Pharmaceutical Science
- Array BioPharma
- Ascentage Pharma
- Boehringer Ingelheim
- BridgeBio Pharma
- Carmot Therapeutics
- Frontier Medicines
- Jacobio Pharmaceuticals
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine Co.
- Leidos Biomedical Research
- Mirati Therapeutics
- REVOLUTION Medicines
- Shanghai Euregen Biopharma
- Shanghai Yingli Pharmaceutical
- Singh Biotechnology
- Suzhou Genhouse Bio
- Suzhou Zelgen Biopharmaceuticals
The advancement in the field of biology has led to the discovery of several oncogenes that play a critical role in cancer development and thus presenting researchers with opportunities to target them. KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for the possible development of novel KRAS inhibitors. The future pipeline of this target looks flourishing as several pharmaceutical companies also plan on bringing novel drug candidates against KRAS.
Researchers worldwide have known about KRAS mutations for several years; however, the available therapies against it were proven to be indefinable. But after the approval of first-ever KRAS inhibitor, Lumakras (Sotorasib) developed by Amgen in 2021 for the treatment of patients with advanced KRAS G12C mutated non-small cell lung cancer, the product market showed significant growth in terms of both commercial sale success and enhanced overall survival rates. Its sales grew more than twice in 2022 as compared to 2021 levels. The drug is the first ever targeted anti-cancer treatment drug against KRAS mutations.
Furthermore, Qiagen also launched Therascreen KRAS RGQ PCR Kit after it received US regulatory approval as a companion diagnostic in aiding the diagnosis of non-small cell lung cancer. This was the first companion diagnostic kit to have received premarket approval from the US FDA. Nevertheless, additional progress has been made in the industry and FDA has further approved companion diagnosis kits. In December 2022 Agilent Resolution's ctDx FIRST was granted approval by the FDA as a companion diagnostic for patients with NSCLC.
The ever-increasing cases of cancer and the ability of the tumor to develop new and frequent mutations signify an unmet need for advancement of novel therapies in the management and treatment of cancer. However, with discoveries like that of Kristen rat sarcoma viral oncogene homolog (KRAS), the future of cancer-targeted therapies is something to look forward to. It is both interesting and concerning how KRAS mutations play a significant role in the pathogenesis and proliferation of cancer.
The market for KRAS-targeted drugs is poised with exponential growth with several factors determining its potential. The KRAS market is widely supported by the accelerating trend of preclinical and in vitro studies which has increased the number of patients that are seeking out treatment opportunities. The rising demand for this therapy has resulted in increasing acceptance of cancer management treatments. The market expects new medications to swiftly and rapidly enter the commercial sector.
There are also factors that will be challenging the future potential of this market. With increased research and development activity, there also increases in the number of competitors in the market. Drug manufacturers need to develop medications that have innovation and creativity and the ability to show better outcomes than its opponents. Currently, Amgen is in the lead for KRAS targeted therapy market but with the incoming of more drugs in the future, some challenges are bound to be faced by the company if it wants to keep its position as the topmost stakeholder in the KRAS inhibitors drug market.
For instance, on December 2022, the US FDA granted accelerated approval to Mirati Therapeutics' Adagrasib (Krazati) which is a RAS GTPase family inhibitor for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. This approval was based on KRYSTAL-1, a multicenter, open-label clinical trial and the indication was approved under accelerated approval based on the overall response rate and duration of response.
For more information about this report visit https://www.researchandmarkets.com/r/638lcu-kras?w=4
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900